Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Synacor Inc (SYNC)

Synacor Inc (SYNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Centre Lane Partners Successfully Completes Tender Offer for Shares of Synacor

Synacor, Inc. (Nasdaq: SYNC) (“Synacor”), today announced that Centre Lane Partners (“Centre Lane”), a private investment firm that invests in the equity and debt of middle market companies in...

SYNC : 2.19 (-0.45%)
Synacor Reports Fourth Quarter and Full-Year 2020 Financial Results

Synacor, Inc. (Nasdaq: SYNC), a leading provider of cloud-based Collaboration and Identity Management software and services serving global enterprises, video, internet and communications providers, and...

SYNC : 2.19 (-0.45%)
SYNACOR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Synacor, Inc. - SYNC

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Synacor, Inc. (NasdaqGM: SYNC) to an affiliate...

SYNC : 2.19 (-0.45%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates CUB, SYNC, PTVCA, SNCA; Shareholders Are Encouraged to Contact the Firm

NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

CUB : 10.02 (-0.03%)
SYNC : 2.19 (-0.45%)
PTVCA : 23.27 (+0.04%)
SNCA : 9.9600 (-1.19%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Buyouts

WILMINGTON, Del., March 02, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating:

CLGX : 80.00 (+0.59%)
SYNC : 2.19 (-0.45%)
CUB : 10.02 (-0.03%)
CMD : 80.37 (-1.18%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, CLGX, SYNC, NK; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

MDCA : 5.42 (-3.39%)
CLGX : 80.00 (+0.59%)
SYNC : 2.19 (-0.45%)
NK : 32.49 (+14.89%)
SYNACOR (SYNC) SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Synacor Inc. Following Agreement to Sell the Company for $2.20 Per Share

PHILADELPHIA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Synacor, Inc. (Nasdaq: SYNC) (“Synacor” or the “Company”) on behalf of the Company’s shareholders....

SYNC : 2.19 (-0.45%)
Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders Are Encouraged to Contact the Firm – CLGX, PRSP, MTSC, SYNC

NEW YORK, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

CLGX : 80.00 (+0.59%)
PRSP : 29.34 (unch)
MTSC : 58.49 (-0.02%)
SYNC : 2.19 (-0.45%)
SYNACOR ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SYNC and Encourages Investors to Contact the Firm

NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Synacor,...

SYNC : 2.19 (-0.45%)

Barchart Exclusives

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy
Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a valuation a third cheaper than competitor, Eli Lilly. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar